Literature DB >> 23264095

Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy.

M Rapicetta1, R Monarca, L A Kondili, P Chionne, E Madonna, G Madeddu, A Soddu, A Candido, S Carbonara, M S Mura, G Starnini, S Babudieri.   

Abstract

PURPOSE: The prevalence of anti-hepatitis E virus (HEV) and anti-hepatitis A virus (HAV), as well as the possible links with socio-demographic and other viral risks factors, were evaluated in an inmates population.
METHODS: The study population consisted of 973 consecutively recruited inmates of eight Italian prisons.
RESULTS: The anti-HEV prevalence was 11.6 % (113/973). It increased significantly by age (χ(2) for linear trend: p = 0.001) and was significantly higher among non-Italian compared to Italian inmates (15.3 vs. 10.7 %, respectively). Age >40 years [odds ratio (OR) 2.1; 95 % confidence interval (CI) 1.4-3.1], non-Italian citizenship (OR 1.8; 95 % CI 1.1-2.9) and anti-HIV seropositivity (OR 2.2; 95 % CI 1.2-4.2) were the only factors independently associated to anti-HEV positivity by logistic regression analysis. The overall anti-HAV prevalence was 86.4 %, and was significantly higher in non-Italian compared to Italian prisoners (92.6 vs. 84.9 %, respectively; p = 0.02). Age older than 40 years (OR 3.6; 95 % CI 2.2-5.9), <5 years formal education (OR 2.1; 95 % CI 1.3-3.2) and non-Italian nationality (OR 2.7; 95 % CI 1.5-4.8) were factors independently associated to anti-HAV positivity by the logistic regression analysis.
CONCLUSIONS: Compared to the general population, significantly higher anti-HEV and anti-HAV prevalences were observed in an inmates population in Italy. Old age and non-Italian nationality were factors independently related to both HEV and HAV exposures. This data suggest the important role of low socio-economic factors in the transmission of both infections in high-risk populations. The possible epidemiological and/or pathogenetic links between HEV and HIV exposures need to be studied further.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23264095     DOI: 10.1007/s15010-012-0385-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  37 in total

1.  Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus.

Authors:  Morag Ferguson; Dawn Walker; Eric Mast; Howard Fields
Journal:  Biologicals       Date:  2002-03       Impact factor: 1.856

2.  Multiple viral hepatitis in injection drug users and associated risk factors.

Authors:  Jens Reimer; Juergen Lorenzen; Bernhard Baetz; Benedikt Fischer; Juergen Rehm; Christian Haasen; Markus Backmund
Journal:  J Gastroenterol Hepatol       Date:  2007-01       Impact factor: 4.029

3.  Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study.

Authors:  Filippo Ansaldi; Bianca Bruzzone; Maria Cristina Rota; Antonino Bella; Marta Ciofi degli Atti; Paolo Durando; Roberto Gasparini; Giancarlo Icardi
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

Review 4.  Serological diagnostics of hepatitis E virus infection.

Authors:  Yury Khudyakov; Saleem Kamili
Journal:  Virus Res       Date:  2011-06-15       Impact factor: 3.303

5.  Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan.

Authors:  Abdul M Kazi; Sharaf A Shah; Cathy A Jenkins; Bryan E Shepherd; Sten H Vermund
Journal:  Int J Infect Dis       Date:  2010-03-01       Impact factor: 3.623

6.  An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4.

Authors:  Yi-Hua Zhou; Robert H Purcell; Suzanne U Emerson
Journal:  Vaccine       Date:  2004-06-30       Impact factor: 3.641

7.  Hepatitis A and E: update on prevention and epidemiology.

Authors:  David FitzSimons; Greet Hendrickx; Alex Vorsters; Pierre Van Damme
Journal:  Vaccine       Date:  2009-11-17       Impact factor: 3.641

8.  Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control.

Authors:  D Whiteman; B McCall; A Falconer
Journal:  J Viral Hepat       Date:  1998-07       Impact factor: 3.728

9.  Systematic screening for novel, serologically reactive Hepatitis E Virus epitopes.

Authors:  Andreas Osterman; Maria Guadalupe Vizoso Pinto; Rudolf Haase; Hans Nitschko; Simone Jäger; Michaela Sander; Manfred Motz; Ulrich Mohn; Armin Baiker
Journal:  Virol J       Date:  2012-01-23       Impact factor: 4.099

10.  Testing for sexually transmitted infections and blood borne viruses on admission to Western Australian prisons.

Authors:  Rochelle E Watkins; Donna B Mak; Crystal Connelly
Journal:  BMC Public Health       Date:  2009-10-13       Impact factor: 3.295

View more
  11 in total

Review 1.  Hepatitis E virus in the countries of the Middle East and North Africa region: an awareness of an infectious threat to blood safety.

Authors:  Soha Yazbek; Khalil Kreidieh; Sami Ramia
Journal:  Infection       Date:  2015-06-26       Impact factor: 3.553

2.  Binding Preference of Anti-HEV Antibodies in Sera Collected in Algeria for Antigens Derived From HEV Genotype 1‏.

Authors:  Nouredine Behloul; Min Zhang; Jihong Meng
Journal:  Hepat Mon       Date:  2016-07-20       Impact factor: 0.660

3.  Seroprevalence of hepatitis E virus differs in Dutch and first generation migrant populations in Amsterdam, the Netherlands: a cross-sectional study.

Authors:  S Sadik; G G C van Rijckevorsel; M S van Rooijen; G J B Sonder; S M Bruisten
Journal:  BMC Infect Dis       Date:  2016-11-08       Impact factor: 3.090

4.  Detection and Molecular Characterisation of Swine Hepatitis E Virus in Brescia Province, Italy.

Authors:  Enrico Pavoni; Ilaria Barbieri; Barbara Bertasi; Guerino Lombardi; Giuseppe Giangrosso; Paolo Cordioli; Marina Nadia Losio
Journal:  Ital J Food Saf       Date:  2015-05-28

Review 5.  Hepatitis E Virus in Industrialized Countries: The Silent Threat.

Authors:  Pilar Clemente-Casares; Carlota Ramos-Romero; Eugenio Ramirez-Gonzalez; Antonio Mas
Journal:  Biomed Res Int       Date:  2016-12-14       Impact factor: 3.411

6.  Seroprevalence of anti-hepatitis E antibodies and antigens among HIV-infected patients in Fars Province, southern Iran.

Authors:  Reza Shahriarirad; Amirhossein Erfani; Mohammad Rastegarian; Ali Zeighami; Nasir Arefkhah; Fariba Ghorbani; Jamal Sarvari; Bahador Sarkari
Journal:  Virol J       Date:  2020-07-17       Impact factor: 4.099

7.  Systematic review and meta-analysis of the seroprevalence of hepatitis E virus in the general population across non-endemic countries.

Authors:  Barbara Wilhelm; Lisa Waddell; Judy Greig; Ian Young
Journal:  PLoS One       Date:  2019-06-07       Impact factor: 3.240

8.  Hepatitis E Infection in HIV-Infected Patients.

Authors:  Antonio Rivero-Juarez; Pedro Lopez-Lopez; Mario Frias; Antonio Rivero
Journal:  Front Microbiol       Date:  2019-06-26       Impact factor: 5.640

Review 9.  Vaccinations in prisons: A shot in the arm for community health.

Authors:  Víctor-Guillermo Sequera; Salomé Valencia; Alberto L García-Basteiro; Andrés Marco; José M Bayas
Journal:  Hum Vaccin Immunother       Date:  2015-07-09       Impact factor: 3.452

10.  Hepatitis E virus among persons who inject drugs, San Diego, California, USA, 2009-2010.

Authors:  Reena Mahajan; Melissa G Collier; Saleem Kamili; Jan Drobeniuc; Jazmine Cuevas-Mota; Richard S Garfein; Eyasu Teshale
Journal:  Emerg Infect Dis       Date:  2013-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.